Come and join us for a live IP webinar and learn about top things you should know about pharmaceutical patenting in Russia. The webinar will be held by our European Patent Attorney Linda Norrgård on 8 April at 4.30 pm EEST. The webinar is free of charge and all registrants will receive a link to the recording after the webinar.
In this webinar you will hear specifics about pharmaceutical patenting in Russia. We will cover common patenting issues of pharmaceutical patenting with useful strategies and practical case examples. You can also suggest topics that we should cover in this webinar.
- Particularly pharmaceutical companies operating in or considering entry into the Russian market
- Pharmaceutical companies filing in Russia
- Patent agencies that represent clients filing in Russia
You’ll find out
- An overview of pharmaceutical patenting issues in Russia e.g. antibodies and medical uses
- Useful strategies
- Useful and practical case examples
Linda Norrgård works as a Team Leader for Papula-Nevinpat’s Chemistry and Process Technology Team.
Linda started her IP career in 2008. She has spent most of her career in various Finnish patent firms, but has also worked in the industrial sector. She has prosecuted a wide range of inventions, with a special focus on polymer technology, organic chemistry (medicinal chemistry), and process and food technology. Linda joined Papula-Nevinpat in 2019.
Linda has solid experience in all stages of patent prosecution and defense. She has extensive experience in patent disputes, such as oppositions and appeals, both in Finland and before the European Patent Office. She has also completed an internship for patent professionals – Praktika Intern – with the European Patent Office in 2011.
In the past few years, Linda has worked in close collaboration with startups, advising startup entrepreneurs on IP protection. She has also been a frequent speaker at various startup events and training programs. Her experience with startups has given her a good sense of perspective on the challenges new businesses are facing in IP issues.